US 12,391,722 B2
Stabilized nucleic acids encoding messenger ribonucleic acid (mRNA)
Christian Dombrowski, Auburndale, MA (US)
Assigned to Intellia Therapeutics, Inc., Cambridge, MA (US)
Filed by Intellia Therapeutics, Inc., Cambridge, MA (US)
Filed on May 1, 2023, as Appl. No. 18/310,298.
Application 18/310,298 is a continuation of application No. 16/791,076, filed on Feb. 14, 2020, granted, now 11,673,911.
Application 16/791,076 is a continuation of application No. PCT/US2018/046772, filed on Aug. 14, 2018.
Claims priority of provisional application 62/545,883, filed on Aug. 15, 2017.
Prior Publication US 2023/0271997 A1, Aug. 31, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12N 15/63 (2006.01); C07H 21/02 (2006.01); C12N 15/11 (2006.01); C12N 15/70 (2006.01); C07K 14/475 (2006.01); C07K 14/52 (2006.01); C12N 9/22 (2006.01)
CPC C07H 21/02 (2013.01) [C12N 15/11 (2013.01); C12N 15/63 (2013.01); C07K 14/475 (2013.01); C07K 14/521 (2013.01); C12N 9/22 (2013.01)] 23 Claims
 
1. A DNA comprising nucleotides encoding a poly-adenylated (poly-A) tail located 3′ to nucleotides encoding a protein of interest, wherein the poly-A tail comprises:
(a) a plurality of homopolymer sequences of 8, 9, 10, 11, and/or 12 consecutive adenine (A) nucleotides; and
(b) an interrupting sequence between each homopolymer sequence, wherein the interrupting sequence comprises:
(i) a dinucleotide comprising two consecutive non-adenine nucleotides; or
(ii) a trinucleotide that does not include a terminal adenine (A).